Patents by Inventor Mark Varney

Mark Varney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250388558
    Abstract: Disclosed herein are substituted compounds, salts, and pharmaceutical formulations thereof, for the treatment of a central nervous system disease or disorder.
    Type: Application
    Filed: June 24, 2025
    Publication date: December 25, 2025
    Inventors: Mark VARNEY, Leslie Joseph STREET, Afshin GHAVAMI, Daniela BRUNNER, Gang ZHOU
  • Patent number: 12472169
    Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, wherein the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: November 18, 2025
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Bruno Paillard, Laurence Del Frari, Valérie Brunner, Adrian Newman Tancredi, Mark Varney
  • Publication number: 20250304546
    Abstract: Disclosed herein are substituted compounds, salts, and pharmaceutical formulations thereof, for the treatment of a central nervous system disease or disorder.
    Type: Application
    Filed: March 27, 2025
    Publication date: October 2, 2025
    Inventors: Mark VARNEY, Leslie Joseph STREET, Afshin GHAVAMI, Daniela BRUNNER, Gang ZHOU
  • Publication number: 20250243173
    Abstract: Disclosed herein are substituted compounds, salts, and pharmaceutical formulations thereof, for the treatment of a central nervous system disease or disorder.
    Type: Application
    Filed: March 20, 2025
    Publication date: July 31, 2025
    Inventors: Mark VARNEY, Leslie Joseph STREET, Afshin GHAVAMI, Daniela BRUNNER, Gang ZHOU
  • Publication number: 20250236602
    Abstract: Disclosed herein are substituted compounds, salts, and pharmaceutical formulations thereof, for the treatment of a central nervous system disease or disorder.
    Type: Application
    Filed: January 23, 2025
    Publication date: July 24, 2025
    Inventors: Mark VARNEY, Leslie Joseph STREET, Afshin GHAVAMI, Daniela BRUNNER, Gang ZHOU
  • Publication number: 20250129035
    Abstract: Disclosed herein are substituted compounds, salts, and pharmaceutical formulations thereof, for the treatment of a central nervous system disease or disorder.
    Type: Application
    Filed: October 14, 2024
    Publication date: April 24, 2025
    Inventors: Mark VARNEY, Leslie Joseph STREET, Afshin GHAVAMI, Daniela BRUNNER, Gang ZHOU
  • Publication number: 20210338646
    Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, wherein the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
    Type: Application
    Filed: June 25, 2021
    Publication date: November 4, 2021
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Bruno PAILLARD, Laurence DEL FRARI, Valérie BRUNNER, Adrian NEWMAN TANCREDI, Mark VARNEY
  • Patent number: 11090298
    Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, wherein the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: August 17, 2021
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Bruno Paillard, Laurence Del Frari, Valérie Brunner, Adrian Newman Tancredi, Mark Varney
  • Publication number: 20200138800
    Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, wherein the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
    Type: Application
    Filed: December 17, 2019
    Publication date: May 7, 2020
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Bruno PAILLARD, Laurence DEL FRARI, Valérie BRUNNER, Adrian NEWMAN TANCREDI, Mark VARNEY
  • Patent number: 10548885
    Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, where in the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: February 4, 2020
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Bruno Paillard, Laurence Del Frari, Valérie Brunner, Adrian Newman Tancredi, Mark Varney
  • Publication number: 20170239231
    Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, where in the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
    Type: Application
    Filed: July 9, 2015
    Publication date: August 24, 2017
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Bruno PAILLARD, Laurence DEL FRARI, Valérie BRUNNER, Adrian NEWMAN TANCREDI, Mark VARNEY
  • Publication number: 20150377821
    Abstract: A sensor for sensing a target substance in a target substance is provided, the sensor comprising: a sensing element disposed to be exposed to the gas stream, the sensing element comprising: a working electrode; a counter electrode; and a layer of ion exchange material extending between the working electrode and the counter-electrode; whereby contact of the ion exchange layer with the gas stream firms an electrical contact between the working and counter electrodes.
    Type: Application
    Filed: April 16, 2015
    Publication date: December 31, 2015
    Inventors: Mark Varney, Michael Garrett
  • Publication number: 20140315910
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
    Type: Application
    Filed: June 27, 2014
    Publication date: October 23, 2014
    Inventors: Judy Caron, Thomas Wessel, Karim LALJI, Mark Varney, Roger P. Bakale, Surendra P. Singh, H. Scott Wilkinson, Xiping Su, Zhengxu Han, Stefan G. Koenig
  • Patent number: 8329950
    Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: December 11, 2012
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Judy Caron, Thomas Wessel, Karim Lalji, Mark Varney, Roger P. Bakale, Surendra P. Singh, H. Scott Wilkinson, Xiping Su, Zhengxu Han, Stefan G. Koenig
  • Publication number: 20100264042
    Abstract: A method of determining the general or a specific condition of a subject is disclosed, the method comprising measuring the concentration of each of a plurality of components in a single sample of the gas stream exhaled by the subject; and generating information regarding the concentration of each of the plurality of components such that the concentrations of the components are directly comparable. The method is particularly suitable for assessing the condition of the respiratory system of a subject. The method preferably employs electrochemical sensors to measure the concentration of the target components in the exhaled gas stream.
    Type: Application
    Filed: October 24, 2008
    Publication date: October 21, 2010
    Applicant: ANAXSYS TECHNOLOGY LTD
    Inventors: Mark Varney, Michael Garrett
  • Publication number: 20100175699
    Abstract: A sensor assembly for monitoring the respiration pattern of a subject is disclosed, the sensor comprising a sensor element for exposing to a gas stream exhaled by the subject comprising a first electrode, a second electrode and an active layer extending between the first and second electrodes to provide an electrical path therebetween, the sensor element being responsive to the concentration of water vapour in the gas stream exhaled by the subject, whereby the conductivity of the path between the electrodes varies in response to changes in the concentration of water vapour; a processor for determining the pattern of respiration of the subject; and means for displaying information relating to the determined respiration pattern to a user. The sensor assembly is particular suitable for measuring the respiration rate and/or depth of respiration of the subject. The sensor and method find particular application in the diagnosis and treatment of sleep apnea.
    Type: Application
    Filed: April 10, 2008
    Publication date: July 15, 2010
    Applicant: ANAXSYS TECHNOLOGY LTD
    Inventors: Mark Varney, Michael Garrett, Deryk Williams, John Beadle
  • Publication number: 20100133120
    Abstract: An electrochemical sensor (40) is provided, the sensor comprising a working electrode (44); a counter electrode (46); and an ionic liquid medium extending between the working electrode and the counter electrode, the ionic liquid medium comprising an ionic liquid retained in a support material. The ionic liquid may comprise a cation selected from 1-alkyl-3-methylimidazolium ([CnMIM]), N-alkylpyridinium, tetraalkylammonium or tetraalkylphosphonium cations and an anion selected from hexafluorophosphate [PF6]; tetrafluoroborate [BF4]; trifluoromethylsulfonate [CF3SO3]; bis[(trifluoromethyl)sulfonyl]amide [(CF3SO2)2N]; trifluoroethanoate [CF3CO2]; acetate [CH3CO2]; nitrate, and halides, including fluoride [F] 1 chloride [Cl], and bromide [Br]. The sensor is particularly useful in the detection of gaseous components in the exhaled breath of a subject and for use in monitoring the lung function of the subject, for example to identify the onset of asthma and/or COPD.
    Type: Application
    Filed: March 17, 2008
    Publication date: June 3, 2010
    Applicant: ANAXSYS TECHNOLOGY LTD
    Inventors: Mark Varney, Micheal Garrett, Deryk Williams, Francis Marken
  • Publication number: 20100050735
    Abstract: A sensor for sensing a target substance in a gas stream is provided, the sensor comprising: a sensing element disposed to be exposed to the gas stream, the sensing element comprising: a working electrode; a counter electrode; and a layer of ion exchange material extending between the working electrode and the counter electrode; whereby contact of the ion exchange layer with the gas stream forms an electrical contact between the working and counter electrodes.
    Type: Application
    Filed: July 20, 2007
    Publication date: March 4, 2010
    Inventors: Mark Varney, Michael Garrett
  • Publication number: 20090272656
    Abstract: A method for the determination of the carbon dioxide content of an exhaled gas stream is provided, the method comprising measuring the water vapour content of the exhaled gas stream, and determining the concentration of carbon dioxide in the exhaled gas stream from the measured water vapour content. A particular method comprises causing the gas stream to impinge on a sensing element comprising a working electrode and a counter electrode; applying an electric potential across the working electrode and counter electrode; measuring the current flowing between the working electrode and counter electrode as a result of the applied potential; and determining from the measured current flow an indication of the concentration of the water vapour in the gas stream. A sensor is also described.
    Type: Application
    Filed: October 17, 2007
    Publication date: November 5, 2009
    Inventors: Mark Varney, Michael Garrett, Deryk Williams
  • Publication number: 20090054798
    Abstract: An apparatus for monitoring the respiration of a subject, the apparatus comprises means for detecting the concentration of each of oxygen, carbon dioxide and nitric oxide in an inspired and/or exhaled gaseous stream of a subject; and a display for displaying the concentration of each of oxygen, carbon dioxide and nitric oxide. A method for monitoring the respiration of a subject comprises analysing the composition of the inspired and/or exhaled gas of the subject and determining the concentration of carbon dioxide, oxygen and nitric oxide in the gas; and displaying the results of the analysis on a display to provide an indication of the respiratory state of the subject. A method of determining the extent of resuscitation of a patient comprises measuring the concentration of carbon dioxide, oxygen and nitric oxide in the inspired gas stream and/or exhaled gas stream of the subject.
    Type: Application
    Filed: November 22, 2005
    Publication date: February 26, 2009
    Applicant: ASTHMA ALERT LIMITED
    Inventors: Mark Varney, Michael Ernest Garrett, Deryk Williams